Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma

Overexpression of programmed death‐1 (PD‐1) ligands contributes to an immunosuppressive microenvironment. Nivolumab is a PD‐1‐blocking antibody that inhibits the PD‐1 pathway and showed good efficacy in several types of malignancy. This phase II study examined the efficacy and safety of nivolumab in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Maruyama, Dai, Hatake, Kiyohiko, Kinoshita, Tomohiro, Fukuhara, Noriko, Choi, Ilseung, Taniwaki, Masafumi, Ando, Kiyoshi, Terui, Yasuhito, Higuchi, Yusuke, Onishi, Yasushi, Abe, Yasunobu, Kobayashi, Tsutomu, Shirasugi, Yukari, Tobinai, Kensei
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2017
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448600/
https://ncbi.nlm.nih.gov/pubmed/28267244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13230
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky